Methotrexate and Omeprazole Interaction Guidelines

Patient Management and Monitoring

• The British Association of Dermatologists recommends performing a comprehensive medication review to identify all potential drug interactions, specifically documenting PPI use, before starting methotrexate therapy 1
• The British Journal of Dermatology suggests that if omeprazole is being used, consider switching to an H2-receptor antagonist before initiating methotrexate therapy, as this may reduce the risk of methotrexate toxicity 1
• Patients on both methotrexate and omeprazole should be monitored every 2-4 weeks initially, then every 1-3 months if stable, with more frequent monitoring when both drugs are used together, according to the British Journal of Dermatology and the Journal of the American Academy of Dermatology 1, 2
• The British Journal of Dermatology recommends monitoring renal function (BUN and creatinine) every 2-3 months, as renal impairment significantly increases interaction risk 1
• Elderly patients with age-related decline in renal function are at higher risk for methotrexate accumulation when combined with omeprazole, as noted by the British Journal of Dermatology 1
• Patients should be educated to immediately report signs of methotrexate toxicity, including unusual bruising or bleeding, mouth sores, severe nausea/vomiting, dark urine, or signs of infection, as advised by the British Journal of Dermatology 1
• The British Association of Dermatologists guidelines list proton pump inhibitors as drugs that may increase methotrexate toxicity through possible reduction in renal elimination 1
• The Joint AAD-NPF guidelines emphasize ongoing medication review to identify drug interactions that may increase methotrexate toxicity 2